Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses
Conditions: HIV Infections; HBV Coinfection Interventions: Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) Sponsors: ANRS, Emerging Infectious Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
Conditions: HIV-1-infection Interventions: Drug: F/TAF (High Dose Tablet); Drug: F/TAF (Low Dose Tablet); Drug: F/TAF (Lowest Dose Tablet); Drug: F/TAF (High Dose TOS); Drug: F/TAF (Low Dose TOS); Drug: F/TAF (Lowest Dose TOS); Drug: E/C/F/TAF; Drug: E/C/F/TAF (Low Dose); Drug: Cobicistat (High Dose); Drug: Cobicistat (Low Dose); Drug: Cobicistat (TOS); Drug: B/F/TAF (High Dose); Drug: B/F/TAF (Low Dose); Drug: B/F/TAF (High Dose TOS); Drug: B/F/TAF (Low Dose TOS); Drug: B/F/TAF (Lowest Dose TOS); Drug: 3rd ARV Agent; Drug: Nucleos(t)ide reverse transcriptase inhibitors (NRTI); Drug: ATV; Drug: DRV; Drug: Lopinavir Boosted...
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
Conditions: COVID-19 Interventions: Drug: nirmatrelvir, ritonavir; Other: Controls Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Study of WPV01 in Healthy Subjects
Conditions: Healthy Participants Interventions: Drug: WPV01 Dose 1-4; Drug: WPV01 Dose 5-8 and Ritonavir; Drug: WPV01 Dose 9-12; Drug: WPV01 Dose 13-15 and Ritonavir; Drug: WPV01 Dose 16 Sponsors: Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants
Conditions: Healthy Participant Interventions: Drug: GST-HG171/Ritonavir; Drug: Itraconazole; Drug: GST-HG171/Ritonavir Sponsors: Fujian Akeylink Biotechnology Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
Conditions: COVID-19 Interventions: Drug: SoC; Other: Disease description Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
Conditions: COVID-19 Respiratory Infection Interventions: Drug: GST-HG171/ritonavir; Drug: ritonavir Sponsors: Fujian Akeylink Biotechnology Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
A Study to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Condition: Covid-19 Intervention: Drug: nirmatrelvir, ritonavir Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials
